PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
PDS Biotechnology Corp <PDSB.OQ> expected to post a loss of 10 cents a share - Earnings Preview
PDS Biotechnology Corp PDSB.OQ PDSB.O is expected to show no change in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2026
LSEG's mean analyst estimate for PDS Biotechnology Corp is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for PDS Biotechnology Corp is $4.50, about 265.9% above its last closing price of $1.23
This summary was machine generated November 9 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing